Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Aficamten's benefits go deeper than symptom relief. New analyses from the ACACIA-HCM trial show the cardiac myosin inhibitor improved diastolic function, NT-proBNP levels, and a wide range of exercise capacity measures in patients with nonobstructive hypertrophic cardiomyopathy (HCM). A novel exercise scoring tool even suggested the drug's effect could translate to a projected 15% survival improvement.
Aficamten's benefits go deeper than symptom relief
New data from the ACACIA-HCM trial, presented at the Heart Failure Society of America Annual Scientific Meeting, reveal that aficamten (Myqorzo, Cytokinetics) delivers broad, clinically meaningful improvements in patients with nonobstructive hypertrophic cardiomyopathy (HCM) — a condition with no previously approved treatments. Beyond improving NYHA functional class and peak oxygen uptake (VO2), the drug also significantly reduced NT-proBNP levels, improved diastolic function, and shrank left atrium volume.
A prespecified analysis went further, using the novel Boston Exercise Aggregate Physiologic Response Score (BEAP-RS) to capture a fuller picture of exercise performance. Aficamten improved BEAP-RS by 2.4 points across all five exercise domains — a magnitude that, when mapped onto the derivation cohort, corresponded to a projected 15% survival improvement.
By the Numbers
Why it matters: Nonobstructive HCM is a largely underserved condition with significant morbidity and no approved therapies. These findings position aficamten as a potentially transformative treatment, with benefits spanning symptoms, cardiac biomarkers, and long-term survival metrics.
